Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Filed: 6 Feb 24, 5:26pm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
TELOMIR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Florida | 87-2606031 |
| (State of Incorporation or Organization) | (I.R.S. Employer Identification No.) |
855 N Wolfe Street, Suite 601 Baltimore, Maryland | 21205 |
| (Address of Principal Executive Offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of Each Class To be Registered | Name of Each Exchange on Which Each Class is to be Registered | |
| Common Stock, no par value | The Nasdaq Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-275534
Securities to be registered pursuant to Section 12(g) of the Act:
None
(Title of class)
INFORMATION REQUIRED IN REGISTRATION STATEMENT
| Item 1. | Description of Registrant’s Securities to be Registered. |
A description of the common stock, no par value (the “Common Stock”), of Telomir Pharmaceuticals, Inc. (the “Registrant”) is contained in the Registrant’s Registration Statement on Form S-1 (File No 333-275534), which was originally filed with the Securities and Exchange Commission (the “Commission”) on November 14, 2023, as amended (the “Registration Statement”), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein. The descriptions of the Common Stock contained in the Registration Statement under “Description of Capital Stock” and the other sections of the Registration Statement cross-referenced to under “Description of Capital Stock” are incorporated in this Item 1 by reference.
| Item 2. | Exhibits. |
Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized.
| Telomir Pharmaceuticals, Inc. | ||
| By: | /s/ Dr. Christopher Chapman, Jr. | |
| Name: | Dr. Christopher Chapman, Jr. | |
| Title: | Chief Executive Officer | |
| Date: February 6, 2024 | ||